Maa: Uusi-Seelanti
Kieli: englanti
Lähde: Medsafe (Medicines Safety Authority)
Rifampicin 300mg
Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics
Rifampicin 300 mg
300 mg
Capsule
Active: Rifampicin 300mg Excipient: Magnesium stearate Maize starch
Bottle, 1x100, 100 capsules
Prescription
Prescription
sanofi-aventis SpA
Tuberculosis Rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. Rifampicin should be used in conjunction with at least one other antituberculosis medicine. Leprosy Rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. Rifampicin should be used in conjunction with at least one other anti-leprosy drug. Methicillin-resistant Staphylococcal infections (MRSA) Rifampicin can be used as an alternative to vancomycin in the treatment of MRSA. In such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. Serious Staphylococcal Infections Rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. In such circumstances an appropriate companion antibiotic should be employed. Brucellosis Rifampicin may be used for the treatment of brucellosis. In such circumstances doxycycline should also be used. Meningococcal Carriers Rifampicin is indicated for the treatment of asymptomatic carriers of N. meningitidis to eliminate meningococci from the nasopharynx. (Rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). Haemophilus Influenzae Rifampicin is indicated for the treatment of asymptomatic carriers of H influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. Other infections Infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, N gonorrhoeae, Proteus sp., H. influenzae, E. coli and Legionella sp. To prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.
Package - Contents - Shelf Life: Blister pack, PVC/PVdC film with Al/PVdC lidding - 100 capsules - 36 months from date of manufacture stored at or below 25°C - Bottle, - 100 capsules - 48 months from date of manufacture stored at or below 25°C
1969-04-11
Rifadin® INJECTION 1 RIFADIN ® INJECTION CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I BEING GIVEN RIFADIN? Rifadin contains the active ingredient rifampicin. Rifadin is an antibiotic taken with other medicines to treat tuberculosis and is taken to treat leprosy. It is also taken to prevent meningococcal disease and infections caused by Haemophilus Influenza Type B. For more information, see Section 1. Why am I being given Rifadin? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I AM GIVEN RIFADIN? Do not take Rifadin if you have ever had an allergic reaction to Rifadin or any of the ingredients listed at the end of the CMI. Do not take Rifadin if you have jaundice. Do not take Rifadin if you are taking saquinavir or ritonavir. These are medicines used to treat AIDS and HIV. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING OR PLANNING TO BREASTFEED. For more information, see Section 2. What should I know before I am being given Rifadin? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with Rifadin and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW IS RIFADIN GIVEN? Rifadin is diluted and given by intravenous infusion. Rifadin must only be given by a doctor or nurse. More instructions can be found in Section 4. How is Rifadin given? in the full CMI. 5. WHAT SHOULD I KNOW WHILE BEING GIVEN RIFADIN? THINGS YOU SHOULD DO • Remind any doctor, dentist, surgeon or pharmacist you visit that you are using Rifadin. • If you have to have any blood or urine tests tell your doctor you are being given Rifadin. • If you are about to be started on a new medicine, including oral contraceptives, tell your doctor you are taking Rifadin. THINGS YOU SHOULD NOT DO • Do not st Lue koko asiakirja
rifadin-ccdsv18-dsv21-26feb24 Page 1 NEW ZEALAND DATA SHEET 1 RIFADIN 150 MG, 300 MG CAPSULES, 100 MG/5ML SYRUP, AND 600 MG INFUSION Rifadin 150 mg capsules Rifadin 300 mg capsules Rifadin 100 mg/5 mL syrup Rifadin IV 600 mg infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Rifadin 150 mg and 300 mg capsules contain 150 mg and 300 mg of rifampicin per capsule respectively. Rifadin syrup contains 100 mg of rifampicin per 5 mL of syrup. Rifadin IV infusion contains 600 mg rifampicin per vial. Excipients with known effect: Capsules: contain sulfites. Syrup: Methyl hydroxybenzoate, propyl hydroxybenzoate, potassium sorbate, saccharin, sodium metabisulfite. For the full list of excipients, see section 6.1 List of Excipients. 3 PHARMACEUTICAL FORM Capsules: 150 mg (blue/red, marked R-150) 300 mg (red, marked R-300) Syrup: 100 mg/5 mL (red, raspberry flavoured) rifadin-ccdsv18-dsv21-26feb24 Page 2 IV infusion: 600 mg (spongy, fragile amorphous red powder), with 10 mL sterile water for injection solvent 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tuberculosis Rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. Rifampicin should be used in conjunction with at least one other antituberculosis medicine. Leprosy Rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. Rifampicin should be used in conjunction with at least one other anti-leprosy drug. Methicillin-resistant Staphylococcal infections (MRSA) Rifampicin can be used as an alternative to vancomycin in the treatment of MRSA. In such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. Serious Staphylococcal Infections Rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. In such circumstances an appropriate companion antibiotic should be employed (see Section 4.2). Brucellosis Rifam Lue koko asiakirja